Pfizer’s Upjohn Business Sees ‘Expected Drop’ Of 37%

Loss Of Exclusivity For Lyrica Cited As Main Factor

 
• By Akriti Seth
  
Pink_Arrow
Ahead of its merger with Mylan, sales through Pfizer’s Upjohn unit have declined by almost two fifths • Source: Shutterstock

More from Earnings

More from Business